– Sponsored News: Biotech stocks are subject to ups and downs within the investment community. With the news of biologics flooding in, however, the biotech sector is seeing a rebound.
Biologics are, according to experts, different from traditional drugs as they are produced in living systems such as microorganisms or plants or animals and not with synthesized chemicals. This biotechnology specialty is drawing the attention of the big pharma companies because of its achievements.
All major players want to grab a share of the market, which IMS Health analysts predict will reach $390 billion by 2020. If the analysts are correct, biologics will account for nearly one third of all drug spending in the coming years. This is paired with a public marketing plan that emphasizes the fact that biologics are natural derivatives and not man-made to explain why so much money has been poured into this field.
As patent expirations approach and companies look to gain an advantage over their competitors, big pharma will turn to smaller firms to help them get next-generation therapies ahead of the competition.
Enter Endonovo Therapeutics(OTCQB : ENDV), a biotechnology firm that is working on a bioelectronic approach for regenerative medicine via its flagship platform Cytotronics. Biologics are primarily created with recombinant DNA technology. “Endonovo is falling back on its technology, which dates back to research at NASA seeking to develop stem cells and medical devices to treat potential injuries that astronauts might encounter during long term missions in outer space.”To increase stem cell therapeutic properties, Time-Varying Electromagnetic Fields (TVEMF), is used by the company. According to the company, this is achieved by stimulating magnetically induced electric field pathways of cells, tissues, and other organs.
Endonovo CEO Alan Collier describes this technology as “effectively training cells to secrete therapeutic proteins.” The secreted proteins can include those commonly used in biologics, such as G-CSF (granulocyte-colony stimulating factor), GM-CSF (granulocyte-macrophage colony-stimulating factor), erythropoietin and interleukins that are used in angiogenesis, antigentargeting, promoting white blood cell growth to fight infections, and more.
Endonovo has two missions. To validate injecting’s potential “enhanced”Or “trained”stem cells and to deliver a combination of therapeutic proteins to stimulate tissue healing.
Please visit this site for more information about the company’s work. www.endonovo.com.
